论文部分内容阅读
目的:探讨雌激素治疗绝经后泌尿系统感染的临床疗效。方法:收集近3年105例泌尿系统感染患者的临床资料,根据治疗方法差异将所有患者分为对照组和观察组,对照组予常规抗生素抗治疗,观察组同时予小剂量雌激素治疗,比较两组临床疗效、孕产史、前次剖宫产情况距前次剖宫产时间与CSP发生的关系。结果:两组治疗3个月、6个月及9个月后,观察组阴道健康评分分别为(11.1±2.4)分、(10.6±2.5)分及(10.2±2.9)分,显著高于对照组(P<0.05)。治疗后6个月、9个月后,观察组复发率为12.0%(9/75)、18.7%(9/75),显著低于对照组的24.0%(12/50)、28.0%(14/50),差异均具有统计学意义(P<0.05)。两组治疗前的血清E2浓度、子宫内膜厚度、阴道p H差异无统计学意义(P>0.05);治疗后观察组E2水平显著升高、p H值出现降低,与对照组治疗后比较,差异有统计学意义(P<0.05)。观察组子宫内膜厚度有所增加。两组不良反应差异无统计学意义(P>0.05)。结论:阴道局部联合采用雌激素可明显提高患者的临床疗效,减低复发率,且不会增加不良反应发生率。
Objective: To investigate the clinical efficacy of estrogen in the treatment of post-menopausal urinary tract infections. Methods: The clinical data of 105 patients with urinary tract infection in recent 3 years were collected. All patients were divided into control group and observation group according to the difference of treatment methods. The control group was treated with conventional antibiotics, while the observation group was treated with low dose estrogen. The two groups of clinical efficacy, pregnancy history, previous cesarean section from the previous cesarean section time and the relationship between CSP. Results: After 3 months, 6 months and 9 months of treatment, the vaginal health scores of the observation group were (11.1 ± 2.4), (10.6 ± 2.5) and (10.2 ± 2.9) points respectively, which were significantly higher than those of the control Group (P <0.05). The relapse rate was 12.0% (9/75) and 18.7% (9/75) in observation group 6 months and 9 months later, which was significantly lower than that in control group 24.0% (12/50) and 28.0% (14) / 50), the differences were statistically significant (P <0.05). There were no significant differences in serum E2, endometrial thickness and vaginal p H between the two groups before treatment (P> 0.05). After treatment, the level of E2 in the observation group increased significantly and the value of p H decreased. Compared with the control group after treatment , The difference was statistically significant (P <0.05). The observation group, the endometrial thickness has increased. There was no significant difference in adverse reactions between the two groups (P> 0.05). Conclusion: The combination of vaginal local estrogen can significantly improve the clinical efficacy of patients, reduce the recurrence rate, and will not increase the incidence of adverse reactions.